These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 29973237)

  • 21. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
    Mellor HR
    Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.
    Tao Z; Cui Y; Xu X; Han T
    Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2208844119. PubMed ID: 36179047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1.
    Guo C; Zhou N; Lu Y; Mu M; Li Z; Zhang X; Tu L; Du J; Li X; Huang D; Xu Q; Zheng X
    Biomed Pharmacother; 2024 Jan; 170():115955. PubMed ID: 38048735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
    Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
    J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble FGFR4 extracellular domain inhibits FGF19-induced activation of FGFR4 signaling and prevents nonalcoholic fatty liver disease.
    Chen Q; Jiang Y; An Y; Zhao N; Zhao Y; Yu C
    Biochem Biophys Res Commun; 2011 Jun; 409(4):651-6. PubMed ID: 21616061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system.
    Latasa MU; Salis F; Urtasun R; Garcia-Irigoyen O; Elizalde M; Uriarte I; Santamaria M; Feo F; Pascale RM; Prieto J; Berasain C; Avila MA
    PLoS One; 2012; 7(12):e52711. PubMed ID: 23285165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma.
    Huynh H; Prawira A; Le TBU; Vu TC; Hao HX; Huang A; Wang Y; Porta DG
    Exp Mol Med; 2020 Nov; 52(11):1857-1868. PubMed ID: 33235319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration.
    Alvarez-Sola G; Uriarte I; Latasa MU; Fernandez-Barrena MG; Urtasun R; Elizalde M; Barcena-Varela M; Jiménez M; Chang HC; Barbero R; Catalán V; Rodríguez A; Frühbeck G; Gallego-Escuredo JM; Gavaldà-Navarro A; Villarroya F; Rodriguez-Ortigosa CM; Corrales FJ; Prieto J; Berraondo P; Berasain C; Avila MA
    Gut; 2017 Oct; 66(10):1818-1828. PubMed ID: 28119353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma.
    Poh W; Wong W; Ong H; Aung MO; Lim SG; Chua BT; Ho HK
    Mol Cancer; 2012 Mar; 11():14. PubMed ID: 22439738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development.
    Uriarte I; Latasa MU; Carotti S; Fernandez-Barrena MG; Garcia-Irigoyen O; Elizalde M; Urtasun R; Vespasiani-Gentilucci U; Morini S; de Mingo A; Mari M; Corrales FJ; Prieto J; Berasain C; Avila MA
    Int J Cancer; 2015 May; 136(10):2469-75. PubMed ID: 25346390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TGF-β1 Promotes Hepatocellular Carcinoma Invasion and Metastasis via ERK Pathway-Mediated FGFR4 Expression.
    Huang J; Qiu M; Wan L; Wang G; Huang T; Chen Z; Jiang S; Li X; Xie L; Cai L
    Cell Physiol Biochem; 2018; 45(4):1690-1699. PubMed ID: 29490293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
    Hu L; Cong L
    Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
    Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
    Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the Wnt/β-catenin signaling pathway in hepatocellular carcinoma.
    Ye Y; Long X; Zhang L; Chen J; Liu P; Li H; Wei F; Yu W; Ren X; Yu J
    Oncotarget; 2016 Oct; 7(43):70303-70322. PubMed ID: 27611941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential.
    Xie H; Alem Glison DM; Kim RD
    Expert Opin Investig Drugs; 2022 Apr; 31(4):393-400. PubMed ID: 34913780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
    J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LRP16 prevents hepatocellular carcinoma progression through regulation of Wnt/β-catenin signaling.
    Shao L; Jing W; Wang L; Pan F; Wu L; Zhang L; Yang P; Hu M; Fan K
    J Mol Med (Berl); 2018 Jun; 96(6):547-558. PubMed ID: 29748698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
    Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM
    Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-1β inhibits β-Klotho expression and FGF19 signaling in hepatocytes.
    Zhao Y; Meng C; Wang Y; Huang H; Liu W; Zhang JF; Zhao H; Feng B; Leung PS; Xia Y
    Am J Physiol Endocrinol Metab; 2016 Feb; 310(4):E289-300. PubMed ID: 26670488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
    Kim RD; Sarker D; Meyer T; Yau T; Macarulla T; Park JW; Choo SP; Hollebecque A; Sung MW; Lim HY; Mazzaferro V; Trojan J; Zhu AX; Yoon JH; Sharma S; Lin ZZ; Chan SL; Faivre S; Feun LG; Yen CJ; Dufour JF; Palmer DH; Llovet JM; Manoogian M; Tugnait M; Stransky N; Hagel M; Kohl NE; Lengauer C; Sherwin CA; Schmidt-Kittler O; Hoeflich KP; Shi H; Wolf BB; Kang YK
    Cancer Discov; 2019 Dec; 9(12):1696-1707. PubMed ID: 31575541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.